Epilepsy Market Insights Overview, Industry Analysis and Forecasts Report 2032

 

Overview:

Epilepsy can be classed as a major neurological disorder where the brain activity becomes abnormal and triggers unusual behavior and sensations. The disorder is discernible in young children and young adults and requires proper attention in time before it can impact the body in an adverse way.

The Epilepsy Market Share is expected to reach USD 1.10 Billion by 2032 at 7.2% CAGR during the forecast period 2023-2032. The regional market is showing ample scope where a high prevalence of the disease can inspire growth in diverse regions.

In addition, the global market would benefit from the presence of countries in the African region where various global bodies are trying to launch initiatives to assist local doctors in curbing the diseases. However, poor economies can detract the growth rate.

Competitive Landscape:

MRFR’s analysis of various companies to get close to factors that can decipher the market growth and assist in the implementation of several market strategies. The recording of these moves can inspire a better understanding of the global scenario. Epilepsy Market Players are

GlaxoSmithKline PLC (U.K.),

LivaNova PLC (U.K.),

Medtronic PLC (Ireland),

Eisai Co. Ltd. (Japan),

Pfizer Inc. (U.S.),

NeuroPace Inc. (U.S.),

UCB SA (Belgium),

Johnson & Johnson Services Inc. (U.S.),

Novartis AG (Switzerland),

GW Pharmaceuticals PLC (U.K.),

Abbott Laboratories (U.S.). 

These companies are set on a path to solidify their own market stance and improve scopes for expansion in the coming days.

Segmentation:

The report on the epilepsy market insights encompasses segments like by condition, diagnosis & treatment, and end-use to facilitate an easy understanding of the market and gauge well how the regional market would shape up in the coming years.

·        By condition, the market report on epilepsy covers epilepsy drug-resistant/intractable epilepsy and others. The former had a market share of 29.5% in 2017. The global market for the segment can provide ample growth opportunities as the requirement for drug-resistant therapies can trigger better growth. The ‘others’ segment has a market growth possibility of 7.83% CAGR during the forecast period.

·        By diagnosis and treatment, the market report on epilepsy includes diagnosis and treatment. The diagnosis segment can be sub-segmented into blood tests, imaging devices, and others. The treatment segment includes neurostimulation devices, anti-epileptic drugs, ketogenic diet, brain surgery, and others. The treatment segment had 66.2% of the global share in 2017. Cost-efficiency can be taken into consideration to understand market growth possibilities.

·        By end-users, the epilepsy market can include clinics, hospitals, diagnostic centers, ambulatory surgical centers, and others. The hospital segment had a market share of 29.3% in 2017.

Regional Analysis:

The global market, upon considering from a region-specific angle, can be segmented into North America, Europe, and the Asia Pacific as major contributors. It also covers Latin America and the Middle East & Africa (MEA) as countries displaying moderate growth but with the potential to improve scenario. The Americas has better market coverage and it had almost 41% of the global market share in 2017. Europe is on a track to display 8.31% CAGR during the forecast period. The regional market has potential to explore opportunities regarding research and development, and it is getting backed by the constant influx of investments. Countries like the UK, France, Germany, and others are contributing much to take the regional market ahead in the coming years.

The Asia Pacific (APAC) market is showing opportunities to score well past a valuation mark of USD 2,046.57 million by 2023. Most of the traction to grow forward would come from India, South Korea, and China where a large population is triggering high ingress of treatments needed for that.

 

About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

Pharmacogenomics Market Share, Leading Players and Demand Forecast Report 2032

 

Market Overview

According to Market Research Future (MRFR), the Global Pharmacogenomics Market Share is Projected grow at a CAGR of 8.52% Over the Forecast Period 2023-2032.

Market Drivers and Top Barriers

The deciding factors in the pharmacogenomics market growth include the surging expenditure in research and development (R&D) along with the elevating rate of adverse reactions. World over, there has been a rising focus on precision medicine coupled with the growing need for drug safety as well as efficacy, which has led to the market expansion in recent years. On that note, the strong focus on precision medicine is striving to expand the pharmacogenomics market, as the primary aim of precision medicine is integrating genetic as well as environmental information of certain diseases along with their responses to specific treatments.

This factor helps in targeted drug therapies, in addition to the growing adoption of treatment procedures that reduce the side effects and achieve accurate results, which makes extensive use of pharmacogenomics. For instance, in 2015, the United States (U.S.) government had implemented a new precision medicine initiative to augment the development of individualized care, which includes genetic variability for a variety of chronic disorders.

Additionally, the rapid growth in the number of research studies associated with sequencing, particularly next-generation sequencing, will raise the demand for pharmacogenomic tests in the years to come. This factor will play an integral role in market growth to a large extent.

Top Vendors

Pharmacogenomics market players include Assurex Health Inc. (U.S.), Pathway Genomics (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Myriad Genetics, Inc. (U.S.), GeneDx. (U.S.), Future Science Group (U.S.), GeneTech (U.S.), 23andMe, Inc. (U.S.), and others.

Market Opportunities

Pharmacogenomics is considered to be a vital aspect in terms of cancer treatment, having proved to be a favorable option helping with the survival of patients. Over and above that, pharmacogenomics also has managed to reduce the additional cost owing to unresponsive treatment. Therefore, growing use of pharmacogenomics for the treatment of cancer has resulted in numerous significant discoveries, which is bound to contribute to the growth of the worldwide market in the upcoming period.

Market Segmentation

The global pharmacogenomics market outlook has been segmented on the basis of technology, application, and end user.

The types of technology in the market include microarray, sequencing, polymerase chain reaction, and others. The sequencing segment is further segmented on the basis of Sanger sequencing, pyrosequencing, next-generation sequencing, and others.

The segments based on application are oncology, cardiology, neurological disorders, and others. The oncology segment can be considered for breast cancer, lung cancer, and others.

On the basis of end users, the market is segmented into hospitals, research organizations, academic institute, and others.

Regional Insight

The pharmacogenomics market is spread across the primary regions of the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas has been identified as the dominant region in the global pharmacogenomics market insights, on account of highly-developed healthcare industry coupled with the inclusion of developed countries such as the United States (U.S.) as well as Canada. Furthermore, the expansion of the patient pool suffering from cardiovascular diseases as well as the growing healthcare expenditure is nurturing the growth of the regional market. As per the Centers for Diseases Control and Prevention, in 2015, heart disease had been the main cause of death for men as well as women in the U.S. In addition, the analysis suggested that the spending on healthcare for heart diseases in the country touches the valuation of USD 200 billion every year.

Data analysts concur that Europe stands second in the global pharmacogenomics market, with the Asia Pacific following suit. The surge in the funds for research and development on top of the increasing government support and the expanding patient population will prove to be instrumental in the market growth. Plus, the region also benefits from the primary contribution of the developed nations such as France and Germany with excellent growth prospects in the medical field.

Racing ahead at the fastest growth rate is the region of Asia Pacific, with the primary reasons being the burgeoning patient pool and the progressively growing economies such as India and China in the region. The Indian Brand Equity Foundation had reported in 2016 that the biotech industry in India is expected to arrive at the valuation of USD 100 billion by the year 2025, crossing the value of USD 7 billion it had reached in 2015. The industry is also expected to expand at a growth rate of 30.46% in the mentioned evaluation period, as per reports.

Meanwhile, the growth of the Middle East & Africa market has been inferior to other regions in the global pharmacogenomics market. This stunted growth can be the result of the poor economy, low expenditure on healthcare, and the rigid government policies, particularly in Africa. Concurrently, the substantial portion of the regional market is controlled by the Middle East, with the backing from the well-established healthcare industry combined with the growing healthcare expenditure. Apart from this, developed countries such as Dubai, Saudi Arabia, and Qatar have a big hand in the growth of the Middle East & Africa market.

 

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

 

Vascular Patches Market Share Expected to reach a notable valuation by 2032

 

Market Analysis

The global vascular patches market share is poised to touch at a notable 8.0% CAGR over the predicted years 2023-2032. Vascular patches are utilized in vascular surgeries for closing sutures. In every surgical procedure, the primary closure of sutures needs to be done effectively. Vascular patches are made from synthetic or biological materials and are characterized through excellent biocompatibility. Of the different types, it is the biological vascular patches that are most widely used owing to its various advantages such as excellent biocompatibility, low suture line bleeding, minimum infection rate and ease in use.

There are plentiful factors that is boosting the growth of the vascular patches market. These factors as per the Market Research Future (MRFR) report include rapidly increasing geriatric population, prevalence of vascular diseases, growing number of vascular surgeries being performed, growing use of biological patches, need for minimally invasive surgeries and increasing product launches and research and development investments. On the contrary, scarcity of skilled professional, mishandling, decrease in carotid endarterectomy surgeries owing to low preference are factors that may restrict the growth of the vascular patches market.

Key Players

Vascular patches market players are include Baxter International Inc. (U.S.), Edwards Lifesciences Corporation (U.S.), Labcor Laboratórios Ltda (Brazil), Admedus (Australia), CryoLife, Inc. (U.S.), W. L. Gore & Associates, Inc. (US), LeMaitre Vascular, Inc. (U.S.), Maquet (Germany), B. Braun Melsungen AG (Germany), Terumo Corporation (Japan), C.R. Bard, Inc. (U.S.) and others.

 

Market Segmentation

MRFR report provides an extensive segmental analysis of the vascular patches market on the basis of application, material and end-user.

Based on material, it is segmented into synthetic vascular patches and biologic vascular patches. Of these, the biologic vascular patches will have the maximum share in the market over the predicted years followed by synthetic vascular patches that will grow at the fastest pace.

Based on application, the vascular patches market outlook is segmented into open repair of abdominal aortic aneurysms vascular bypass surgery and carotid endarterectomy. Of these, carotid endarterectomy will dominate the market followed by open repair of abdominal aortic aneurysms vascular bypass surgery which will grow at the fastest rate.

Based on end-user, it is segmented into ambulatory surgical centers, hospitals and clinics and others. Of these, hospitals and clinics will rule the market followed by ambulatory surgical centers that will grow at the fastest pace.

Regional Analysis

By region, the vascular patches market insights covers growth opportunities and latest trends across North America, Europe, Asia Pacific and Middle East and Africa. Of these, North America will domineer the market over the predicted years and is expected to expand at a substantial CAGR. The increasing occurrence of cardiovascular issues in Canada and the US, growing population and increasing per capita healthcare spending will boost the market growth in this region. Also, the rapid uptake of latest devices and technologies in the surgical procedure and the presence of key manufacturers is again boosting the market growth. The vascular patches market in Europe will have the second major share due to the resurging economy, growing awareness regarding vascular patches and procedure advancements and increasing per capita healthcare expenses. The vascular patches market in the APAC region will grow at the fastest pace over the predicted years owing to growing healthcare sector in India and China, increasing geriatric populace, growing awareness regarding healthcare and rising incidence of people suffering from various chronic coronary diseases.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Precision Medicine Market Insights Overview, Industry Analysis and Forecasts Report 2032

 

Overview:

The global precision medicine market size is witnessing unprecedented growth due to people turning their focus more on personal healthcare. It could attain an astonishing CAGR of 12.5% during the forecast period (2023-2032). Precision medicine evolved from the concept that same medicine cannot function equally for two different individuals with the same disease as they have different gene structure. At the same time, medication depends on how well patients can respond to its dosage. Hence, the need for precision medicine. Market Research Future (MRFR), in their report, has included various drivers and segments that can produce a reliable prediction for the future market. Prevalent diseases such as cancer, diabetes, and others are boosting the precision medicine market as treatment of such diseases gets a better result with personalized medicine structure. Furthermore, its impact can significantly lower the cost of treatment.

However, a personal data breach can be seen as a major precision medicine market growth prohibition. The diagnostic cost can incur a high cost, stringent government policies, the risk with hardware and software failure, and lack of medical framework can hold back the market during the forecast period.

Market Insights:

Mergers, acquisitions, collaborations and other strategies dominate the market substantially when it comes to strategic decisions. For instance, Roche purchased Foundation Machine to better their portfolio. On the other hand, New Medicine Partners is trying to increase their market reach by proposing a plan based on personalized medicines to Kazakhstan officials to develop a plant there. 

Global precision medicine market players include Abbott Laboratories (USA), Ab-Biotics SA (USA), Almac Group Ltd. (UK), Asuragen Inc (USA), Biobase GmbH (Germany), Biomérieux SA (France), Caris Life Sciences (USA), Cepheid Inc. (USA), Cetics Healthcare Technologies Gmbh (Germany), GE Healthcare (USA), GlaxoSmithKline PLC (UK), Healthcore Inc. (USA), IBM (USA), Innventis (Israel), Intel Corporation (USA), Johnson & Johnson (USA), Laboratory Corporation Of America Holdings (USA), Medtronic (USA), Molecular Health GmbH (Germany), Novartis (Switzerland), Pfizer Inc. (USA), Qiagen (Germany), Quest Diagnostics Inc (USA), Randox Laboratories Ltd. (UK), Sanofi Pharma (France), Takeda Pharmaceutical Company Limited (Japan), Teva Pharmaceutical Industries Ltd. (Israel), and others.

Industry Trends:

Precision medicine is showing great promise for the cure of the Alzheimer’s disease. Two new drugs are waiting on the sideline for final approval; one called BAN2401 and the other Anavex 2-73. BAN2401’s use on patients shows a reduction in generation of proteins called amyloid plaques that cause memory loss.    

Recently, an article published in SLAS Technology (Society for Laboratory Automation and Screening) revealed that artificial intelligence (AI) is all set to impact precision medicine industry significantly as it can efficiently analyze small datasets and assist in the optimal design of drug combinations.

Segmentation:

The global precision medicine market insights can be segmented by ecosystem, sub-market, and therapeutics.

Based on the ecosystem, the precision medicine market can be segmented into clinical laboratories, diagnostic tool companies, healthcare IT/ big data companies, and pharma & biotech companies. Diagnostic tools segment has the largest market volume.

Sub-market segment of the precision medicine can be segmented by biomarker-based test, companion diagnostics, molecular diagnostics, pharmacogenomics, targeted therapeutics, and others. Company diagnostics is leading the segment.

Therapeutics-based segmentation of the precision medicine market includes cancer/oncology, cardiovascular disease, central nervous system, infectious diseases, and others.

Regional Analysis:

Region-specific analysis of the precision medicine market encompasses North America, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).

North America is the largest market for global precision medicine. The region has superior infrastructure, both in healthcare and biotechnology. It sets up the zone perfectly for research and developments assisting further in new product development.

Europe is the second-largest market for global precision medicine. Various investors are taking an interest in the sector and is helping in the development of new drugs. However, the developing regions market particularly, the APAC will be the fastest growing and is likely to be the key to the future. But the MEA region may not find much thrust due to but can expect steady growth.

 

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

 

Nuclear Imaging Devices Market Share, Size, Trends, Industry Analysis Report to 2032

 

Market Highlights

The global Nuclear Imaging Devices Market Share is expected to grow significantly over the forecast period. It is anticipated that the market is projected to register a CAGR of 5.1% over the forecast period 2023-2032.

The increasing prevalence of cardiovascular disorders is one of the key factors driving the nuclear imaging devices market. As per the report published by the Centers for Disease Control and Prevention (CDC) in 2017, nearly 92.1 million adults were dealing with at least one type of cardiovascular disease.

Various other factors such as the advancements in radiotracers, acceptance of nuclear imaging devices in ambulatory settings, increasing geriatric population, untapped emerging markets, rise in regulatory approvals, and increasing investment on diagnostic imaging centers are also expected to propel the growth of the market.

However, the high cost of the nuclear imaging device, shorter half-life of radiopharmaceuticals can hamper market growth over the forecast period.

Key Players

the global nuclear imaging devices market players are

Philips Healthcare,

Digirad Corporation,

Neusoft Medical Systems Co., Ltd.,

Progenics Pharmaceuticals Inc.,

Cannon Inc.,

Surgiceye GmbH,

CMR Naviscan,

Mediso Medical Imaging Systems Ltd.,

Agfa-Gevaert Group,

General Electric Company,

DDD-Diagnostic A/S,

Spectrum Dynamics Medical,

FMI Medical Systems, Inc.,

Segamicorp, and others.

Segmentation

The global nuclear imaging devices market is segmented based on technology, application, end user, and region.

·        The global nuclear imaging devices market outlook, by technology, is segmented into positron emission tomography (PET), single photon emission computed tomography (SPECT), and planar scintigraphy. The single-photon-emission computed tomography (SPECT) are further classified as hybrid SPECT systems and standalone SPECT systems.

·        Based on application, the market is segmented into oncology, cardiology, neurology, and others.

·        Based on end user, the market is segmented into hospitals, diagnostic imaging centers, and others.

·        The diagnostic imaging centers segment is expected to witness the fastest growth over the forecast period due to rising adoption of nuclear imaging in diagnostic centers.

Regional Analysis

In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and African region.

The nuclear imaging devices market insights in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European nuclear imaging devices market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The nuclear imaging devices market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The nuclear imaging devices market in the Middle East & Africa has been segmented into the Middle East and Africa.

About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

Pacemaker Market Share, Size, Trends, Industry Analysis Report to 2032

 

Market summery -

 

Global Pacemaker Market Share is expected grow a CAGR of 3.60% over the forecast period of 2023-2032, as per the latest study report by Market Research Future (MRFR).

 

Pacemakers regularize heart rhythm by sending electric pulses to the heart and help in restoring cardiac activity. The surge in the prevalence of cardiac diseases has generated high demand for pacemakers which is driving the growth of the global pacemaker market. Atrial fibrillation, in particular, has witnessed a higher incidence rate in recent years which requires pacemakers for remediation. Increase in global geriatric population is also creating a conducive environment for the growth of the market. Atrial fibrillation and cardiac diseases are more prevalent in old patients. As per a 2018 study published in the Aging Medicine, there is 5 to 9% chance of occurrence of atrial fibrillation in patients between the age of 60-80 years and nearly 10% in patients aged over 80 years.

 

 

Technological advancements have resulted in the development of advanced pacemakers which are smaller in size and have longer battery life. Other factors aiding the growth of the market include an elevated level of awareness regarding cardiovascular diseases, improvement in reimbursement scenario, and high healthcare expenditure across the globe.

 

In recent years, various new pacemakers have received clearance from regulatory bodies which also has augmented the growth of the global pacemaker market. However, the approval and marketing if pacemakers are regulated by the US FDA which are stringent considering the degree of risk they pose to patients. Such stringent regulatory requirements might impede the growth of the market. High costs of pacemakers, risks involved in implantation procedures and risks of malfunctioning are other possible bottlenecks.

 

Competitive Landscape

Global pacemaker market players are below

ZOLL Medical Corporation, MEDICO S.p.A, Cordis, Inc., St. Jude Medical Inc., Biotronik GmbH & Co. KG, Boston Scientific Corporation, General Electric Company, Pacetronix, Medtronic Plc, Sorin Group, Edwards Lifesciences, Cook, and Vitatron are the key players in the global pacemaker market.

 

Segmentation

The global pacemaker market outlook has been segmented based on product type, application, implant approach, and end-user.

By product type, the global pacemaker market has been segmented into implantable and external. The implantable segment has been further segmented into single chamber, dual chamber, and biventricular.

By application, the global pacemaker market has been segmented into bradycardia, heart failure, hypertrophic cardiomyopathy, syncope, and others. The bradycardia segment has been further segmented into sinus node dysfunction and AV block.

By implant approach, the global pacemaker market has been segmented into endocardial approach and epicardial approach.

By end-user, the global pacemaker market has been segmented into hospitals & clinics, ambulatory surgical centers, research & academic institutes, and others.

 

Regional Analysis

By region, the global pacemaker market has been segmented into the Americas, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA).

 

The Americas account for the largest share of the global pacemaker market. Presence of a robust healthcare sector and technological advancements accelerate the growth of the market. The FDA has also been approving various novel pacemakers in the region. Moreover, the presence of various medical device manufacturers and surging cases of cardiovascular disorders support market growth in the Americas.

 

Europe follows the Americas closely and ranks second in the global pacemaker market. Growing government support in the form of R&D grants and the growing presence of key players in the region drive the market in Europe. The growing incidence rate of cardiovascular diseases and high healthcare expenditure are other factors substantiating the growth of the market.

 

APAC pacemaker market is driven by the growing prevalence of atrial fibrillation in the region. In addition, the region has emerged as a medical tourism hub which is likely to propel the growth of the market. Increasing healthcare expenditure and the presence of a large pool of cardiac patients also will have a positive impact on market growth.

 

The MEA market is likely to exhibit sluggish growth due to lack of healthcare infrastructure, lack of technical knowledge and less awareness regarding cardiac medical conditions.

 

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Corporate Wellness Market Insights, Global Strategies & Growth Factors

 

Market overview

The global corporate wellness market size is estimated to exhibit growth by expanding at 8.5% during the forecast period 2022-2030 to reach a valuation of USD 114.4 billion by 2030. This growth is attributable to the higher acceptance of corporate wellness programs, which are designed to evaluate the employee’s health.

Additionally, these wellness programs are designed to estimate the probable health risks and promote healthy behavior at the workplace. Thus, these programs promote a healthy environment at workplaces and enhance productivity by lower healthcare spending substantially. Such factors are driving growth of the global corporate wellness market.

Further, the adoption of such programs results in improve morale & quality of work and decreases absenteeism; thus, several organizations are adopting corporate wellness programs. Rising prevalence of obesity, smoking, alcoholism, and other chronic diseases among white-collar workers especially in the private sector are boosting the adoption of corporate wellness. According to the data by the World Health Organization (WHO), more than 1.1 billion people were smoking tobacco in 2015. Additionally, the prevalence of obesity has tripled from the past three decades. Such data are reflecting the need for the adoption of corporate wellness programs among employers to keep their employees healthy to deliver quality work on time. This is a key factor estimated to drive growth of the global corporate wellness market in the coming years.

Competitive Analysis:

The global corporate wellness market players include ComPsych Corporation, SOL Wellness, Wellness Corporate Solutions, LLC, Wellsource, Inc., Truworth Health Technologies Pvt. Ltd., Central Corporate Wellness, Virgin Pulse, EXOS, Marino Wellness, Privia Health, ProvantHealth (Hooper Holmes, Inc.), The Vitality Group, Inc., Sodexo Group, and Bupa Wellness Pty Ltd.

Segmentation:

The global corporate wellness market has been segmented into category, service type, end user, and region.

By service type, the market is segmented into stress management, health risk assessment, nutrition & weight management, fitness, smoking cessation, health screening, and others. Of these, the health risk assessment segment dominated the global corporate wellness market in 2017 owing to the increasing adoption of wellness programs for wellbeing and assessment of health risks of employees. Additionally, implementation of the appropriate intrusion strategies and promotion of adopting a healthy lifestyle are benefiting the segmental growth.

On the basis of category, the market is segmented into psychological therapists, fitness & nutrition consultants, and organizations.

Based on end users, the market is segmented into medium-scale businesses, small-scale businesses, and large-scale businesses.

Regional Analysis:

Regionally, the corporate wellness market insights is segmented into the Americas, Asia-Pacific, Europe, and Middle East & Africa. Of these, North America dominated the global corporate wellness market in 2017 and is estimated to remain dominant during the forecast period owing to the presence of corporate wellness program providers coupled with a substantial increase in the prevalence of chronic diseases in the region. Additionally, the most significant expenditure on healthcare in the region and surge in the adoption of wellness activities in Canada and the U.S.

Further, Europe is likely to hold the second-largest share in the revenue of the corporate wellness market owing to the increasing activeness of European employees and employers. Additionally, corporate wellness programs are increasingly taking a crucial part of medium or large organizations in the region, which is augmenting the growth of the market. The corporate wellness programs have become the strategic priority in European organizations; thus, the market in the region is flourishing continuously. However, the market in the Asia Pacific is estimated to expand by exhibiting a faster CAGR owing to robust industrialization and urbanization in the region. In addition to this, the increasing awareness about the health of employees due to the effects of long working hours and larger workload in countries such as India and China are estimated to benefit the market growth in the coming years as well.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America